30.12

0.92% -0.28

After Hours: 30.19 0.07 +0.23%

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is traded at $30.12, with a volume of 1.86M. It is down -0.92% in the last 24 hours and up +7.84% over the past month. Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Previous Close:

$30.40

Open:

$30.45

24h Volume:

1.86M

Relative Volume:

1.38

Market Cap:

$1.73B

Revenue:

$11.13M

Net Income/Loss:

$-105.04M

P/E Ratio:

-13.35

EPS:

-2.2565

Net Cash Flow:

$-81.54M

1W Performance:

+0.74%

1M Performance:

+7.84%

6M Performance:

+285.17%

1Y Performance:

+217.89%

1-Day Range:

$29.95

$31.74

1-Week Range:

$27.50

$31.74

52-Week Range:

$4.30

$40.37

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1116)

Industry

Biotechnology (621)

Phone

(310) 358-3200

Address

10865 ROAD TO THE CURE, SAN DIEGO, CA

Employee

231

Twitter

@Capricor

Next Earnings Date

2026-03-12

Latest SEC Filings

CAPR's Discussions on Twitter

Compare CAPR vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAPR Capricor Therapeutics Inc	30.12	1.75B	11.13M	-105.04M	-81.54M	-2.2565
VRTX Vertex Pharmaceuticals Inc	447.26	113.44B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	777.25	81.68B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	743.12	45.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	328.73	43.88B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	164.86	35.25B	606.42M	-1.28B	-997.58M	-6.403

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-30-25	Initiated	Alliance Global Partners	Buy
Jun-26-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	Roth Capital	Buy
Oct-21-24	Initiated	Piper Sandler	Overweight
May-17-24	Initiated	Oppenheimer	Outperform
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

Mar 31, 2026

Capricor Therapeutics (NASDAQ: CAPR) proxy: Board nominees, pay and Nippon Shinyaku deals - Stock Titan

Mar 31, 2026

[144] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan

Mar 31, 2026

Mar 30, 2026

Insider Sell: Is Capricor Therapeutics Inc stock a good dividend stock2026 Price Momentum & Safe Capital Preservation Plans - baoquankhu1.vn

Mar 30, 2026

Value Recap: Is Capricor Therapeutics Inc a defensive stock2026 Levels & Weekly High Potential Stock Alerts - baoquankhu1.vn

Mar 30, 2026

Is Capricor Therapeutics Inc stock a good dividend stock2026 Retail Activity & Daily Chart Pattern Signal Reports - baoquankhu1.vn

Mar 30, 2026

Mar 29, 2026

Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance - MSN

Mar 29, 2026

Mar 27, 2026

Capricor (CAPR) EVP and General Counsel exercises options for 2,500 shares - Stock Titan

Mar 27, 2026

Bull Run: Does Capricor Therapeutics Inc stock benefit from AI growth2026 Support & Resistance & Real-Time Sentiment Analysis - baoquankhu1.vn

Mar 27, 2026

CAPR Technical Analysis | Trend, Signals & Chart Patterns | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill

Mar 27, 2026

Mar 25, 2026

Momentum Shift: Is AKAM a top pick in the sectorTreasury Yields & Comprehensive Market Scan Reports - baoquankhu1.vn

Mar 25, 2026

Merger Talk: How does Capricor Therapeutics Inc perform in inflationary periods2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn

Mar 25, 2026

Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo

Mar 25, 2026

Mar 24, 2026

Technical Reactions to CAPR Trends in Macro Strategies - Stock Traders Daily

Mar 24, 2026

Mar 23, 2026

Capricor Therapeutics Tokenized Stock (Ondo) price today, CAPRon to USD live price, marketcap and chart - CoinMarketCap

Mar 23, 2026

Mar 22, 2026

Capricor Therapeutics, Inc.(NasdaqGS:CAPR) added to S&P Biotechnology Select Industry Index - marketscreener.com

Mar 22, 2026

Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus

Mar 22, 2026

Mar 21, 2026

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com

Mar 21, 2026

Mar 20, 2026

Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN

Mar 20, 2026

Mar 19, 2026

Why Capricor Therapeutics (CAPR) Is Down 8.0% After FDA Resumes Deramiocel Review And Phase 3 Update - Sahm

Mar 19, 2026

Mar 18, 2026

Growth Review: Is Capricor Therapeutics Inc a defensive stock2026 EndofYear Setup & Long-Term Safe Return Strategies - baoquankhu1.vn

Mar 18, 2026

Capricor Therapeutics Pipeline Overview: Deramiocel for Muscular Dystrophy and Exosome-Based Vaccine Development (2025-2026) - Minichart

Mar 18, 2026

Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insight - GuruFocus

Mar 18, 2026

Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - 富途牛牛

Mar 18, 2026

Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insi - GuruFocus

Mar 18, 2026

CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 18, 2026

Mar 17, 2026

Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance - Insider Monkey

Mar 17, 2026

Capricor Therapeutics 2025 10-K: Revenue $0, EPS $(2.26) - TradingView

Mar 17, 2026

Deramiocel DMD program and big Nippon Shinyaku deals at Capricor (NASDAQ: CAPR) - Stock Titan

Mar 17, 2026

About Capricor Therapeutics (Ondo Tokenized) - Coinbase

Mar 17, 2026

13 Best Hot Stocks to Buy According to Analysts - Insider Monkey

Mar 17, 2026

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 17, 2026

Mar 16, 2026

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits

Mar 16, 2026

A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data - Sahm

Mar 16, 2026

Q1 Earnings Forecast for CAPR Issued By HC Wainwright - marketbeat.com

Mar 16, 2026

Mar 15, 2026

Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo

Mar 15, 2026

Mar 14, 2026

Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? - Yahoo Finance

Mar 14, 2026

Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative - simplywall.st

Mar 14, 2026

Mar 13, 2026

CAPR Stock: Analyst B. Riley Securities Raises Price Target to $ - GuruFocus

Mar 13, 2026

Capricor Therapeutics Nears Key Milestones After Earnings Call - TipRanks

Mar 13, 2026

Deramiocel Poised to Be First Therapy for DMD's Cardiac and Skeletal Issues - Intellectia AI

Mar 13, 2026